Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. - Wikidata - awgldk - TriplyDB

Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.

Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.

http://www.wikidata.org/entity/Q34775047

about

Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis G-protein-coupled receptors signaling pathways in new antiplatelet drug development Thrombin and vascular inflammation Thrombin receptors and their antagonists: an update on the patent literature Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions.Measurement of platelet aggregation, independently of patient platelet count: a flow-cytometric approach.Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.Signal transduction by protease-activated receptors Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor.Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection.Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar.Tissue factor, blood coagulation, and beyond: an overview.Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Vorapaxar: targeting a novel antiplatelet pathway.Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.Newer agents in antiplatelet therapy: a review.Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us.Total Synthesis of the Galbulimima Alkaloids Himandravine and GB17 Using Biomimetic Diels-Alder Reactions of Double Diene Precursors A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.Total synthesis of the Galbulimima alkaloid (-)-GB17 New paradigms in GPCR drug discovery.SCH 530348: a novel oral thrombin receptor antagonist.Teleocidin A2 inhibits human proteinase-activated receptor 2 signaling in tumor cells.Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease.Platelet thrombin receptor antagonism and atherothrombosis The modification of natural products for medical use.Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.Doxycycline directly targets PAR1 to suppress tumor progression.Vascular PAR-1: activity and antagonism.Mechanism of action and clinical development of platelet thrombin receptor antagonists.Antiplatelet therapy in acute coronary syndromes.Vorapaxar: a novel protease-activated receptor-1 inhibitor.

P2860

Q26745754-951C09F4-680F-48A1-9C14-55CE0D1BB981 Q26783034-CB20BF94-11DB-4BC5-A401-B66EF1A389B4 Q26864951-49624AE7-9322-4353-BF6D-23518320E492 Q28246124-785EA410-79EB-4285-B199-D233045BF308 Q28281696-F16DBBD0-1DA5-422A-B4A9-B8F739315B27 Q30238719-152FA5B2-3029-4B6A-86F1-FA2759BB19B6 Q30486707-429C9E6A-B0C2-41AA-B9E1-B7A66CC9864E Q33438463-7E6086D5-08CB-4AEA-B1D6-51B5BB6C4293 Q33440160-2E7A6741-4CFA-4E14-BD63-B5BF6872BFD9 Q33554381-E753DAE7-2635-48C0-99EE-14C3B1C007D7 Q33685876-CC98976D-84AF-4BF8-A55A-8754EEB8ABA7 Q33870369-A6092CB0-901B-430B-824E-368000519BCA Q34191373-984EAD20-DA83-4C62-85DD-F833CA5C43EF Q34276408-223CE811-C3E6-4716-9218-3D832AB6CDB5 Q34358307-8D436DB6-76AC-416A-8E2D-AB9EEC383370 Q34475362-FF263FC5-AE8C-4B25-907D-3A0EA30718F9 Q34580117-E4E06BCC-8ABA-4BBE-9D40-3F79727573DF Q35197451-0CB60158-A464-4B01-B092-AECC4816A3FA Q35222618-C5CD2463-432B-4BD7-A54C-1DDA4F05F0E4 Q35671956-9B8376D3-1019-4966-8612-F93B66B6A33C Q35752611-FFFDEFDC-2336-4650-A58E-D2E96996096D Q35752810-9D4244DF-78BE-4FE3-BADD-EB83FDD7117D Q35797491-BE77BC71-4533-4FBC-9260-4E2E0619AE5C Q36085620-F0FF57C6-DB42-4F5F-A76A-CA7CCC7AD82C Q36094523-12F78B80-AC0F-482D-96A1-133F23EAFC27 Q36181776-EA188451-8BE1-4A5E-97C7-78E75282594E Q36374457-3CD0A179-C359-46AC-A2AB-363AFD06E138 Q36401433-AA0916FA-A5D9-4F79-B203-B916E99D9255 Q37140411-9E7D5315-B366-45C1-9192-00D27D69A265 Q37588688-11868C4F-39F8-42FB-8BAA-F871742CF4EA Q37591794-E978D8FC-5102-4108-A11C-063B04E0FA33 Q37635262-ECC212A0-4631-4A65-854F-8AD1AED6474F Q37641556-AB5EF375-E500-4C63-B6DB-E095D22CCBBD Q37689655-D7EF2C86-E6B1-421F-9108-E6E8CA6A95F9 Q37716022-1920C829-B04D-4C24-9A36-B19E2AA94E39 Q37725527-DFA7D1E0-0E65-410A-A1C4-3EEC87F8F3E4 Q37763262-837F54F5-6FC9-42E3-80B2-5278BB63FC6A Q37776518-3339E51E-139A-4687-8B7B-3319AFAFEACE Q37798110-A3942165-8528-4B3B-9432-AB197CBB097E Q37912186-61F86D52-9B01-400C-91D8-A39E0C58F116

P2860

Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.

http://www.wikidata.org/entity/Q34775047

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Discovery of a novel, orally a ...... potent antiplatelet activity.

@ast

Discovery of a novel, orally a ...... potent antiplatelet activity.

@en

Discovery of a novel, orally a ...... potent antiplatelet activity.

@nl

type

label

Discovery of a novel, orally a ...... potent antiplatelet activity.

@ast

Discovery of a novel, orally a ...... potent antiplatelet activity.

@en

Discovery of a novel, orally a ...... potent antiplatelet activity.

@nl

prefLabel

Discovery of a novel, orally a ...... potent antiplatelet activity.

@ast

Discovery of a novel, orally a ...... potent antiplatelet activity.

@en

Discovery of a novel, orally a ...... potent antiplatelet activity.

@nl

P1433

Q34775047-0E93E3FE-DE97-4803-826F-F433626D5CD7

P1476

Q34775047-4C0E078D-3A2E-4C3D-A30A-3C12375D0DAC

P2093

Q34775047-096CF287-EAC1-4D2C-A70E-17201C9C2739

Q34775047-101F0B55-B554-4B21-AC0E-1C93E58E0883

Q34775047-309C9162-E755-4D27-A329-FC3A8E723666

Q34775047-3614FEC4-91A3-44BF-8A3A-5368BA9210FD

Q34775047-8070574C-B32D-4300-8952-00B416044A6C

Q34775047-9B0F7AE2-2A57-4525-B1E9-1E0679C36FAE

Q34775047-A4EF6DC9-6ACB-456B-9BCB-91496DC1A5A5

Q34775047-A84B7BE4-26C7-496D-A8B2-3631E792B207

Q34775047-B80361F6-89B1-4A6B-9A25-02BB9B6285BF

Q34775047-BCDE73A5-EA92-43C5-A58B-1E418BE71B87

P304

Q34775047-B3BAAF6F-352D-41AE-A2BD-09D7D52DF026

P31

Q34775047-F979749D-976A-4365-B92F-73C4D3CAC184

P356

Q34775047-F74E6645-4CD4-4476-BCEB-40B7C76A8D82

P407

Q34775047-CFBF143B-60EE-48D6-A04D-1BF55C29CCE2

P433

Q34775047-762ABB3C-032A-4261-B390-24E3DDC67CB1

P478

Q34775047-5A4ED95C-3D34-48E0-B65D-DBBCBA7ADF84

P577

Q34775047-D37E4620-5ABC-498F-B785-80182675A49E

P698

Q34775047-AA88A120-1FB4-4208-883F-CC53273E49F6

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of a novel, orally a ...... potent antiplatelet activity.

@en

P2093

George Boykow

http://www.w3.org/2001/XMLSchema#string

Ho-Sam Ahn

http://www.w3.org/2001/XMLSchema#string

Jacqueline Agans-Fantuzzi

http://www.w3.org/2001/XMLSchema#string

Jairam Palamanda

http://www.w3.org/2001/XMLSchema#string

Madhu Chintala

http://www.w3.org/2001/XMLSchema#string

Michael Graziano

http://www.w3.org/2001/XMLSchema#string

Samuel Chackalamannil

http://www.w3.org/2001/XMLSchema#string

Stan Kurowski

http://www.w3.org/2001/XMLSchema#string

William J Greenlee

http://www.w3.org/2001/XMLSchema#string

Yan Xia

http://www.w3.org/2001/XMLSchema#string

P304

3061-3064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM800180E

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18447380

http://www.w3.org/2001/XMLSchema#string